Crescent Biopharma (NASDAQ:CBIO – Get Free Report) and Scienture (NASDAQ:SCNX – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.
Risk & Volatility
Crescent Biopharma has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500. Comparatively, Scienture has a beta of 3.32, suggesting that its stock price is 232% more volatile than the S&P 500.
Profitability
This table compares Crescent Biopharma and Scienture’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Crescent Biopharma | N/A | -103.44% | -88.19% |
| Scienture | N/A | -56.28% | -44.76% |
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Crescent Biopharma | $11.88 million | 47.89 | -$153.94 million | ($10.91) | -1.89 |
| Scienture | $477,676.00 | 35.13 | -$41.51 million | ($2.51) | -0.16 |
Scienture has lower revenue, but higher earnings than Crescent Biopharma. Crescent Biopharma is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
75.2% of Crescent Biopharma shares are held by institutional investors. Comparatively, 5.7% of Scienture shares are held by institutional investors. 4.0% of Crescent Biopharma shares are held by company insiders. Comparatively, 21.4% of Scienture shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Crescent Biopharma and Scienture, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Crescent Biopharma | 1 | 0 | 5 | 3 | 3.11 |
| Scienture | 1 | 0 | 1 | 0 | 2.00 |
Crescent Biopharma currently has a consensus price target of $28.00, indicating a potential upside of 35.59%. Scienture has a consensus price target of $1.50, indicating a potential upside of 263.20%. Given Scienture’s higher probable upside, analysts plainly believe Scienture is more favorable than Crescent Biopharma.
Summary
Scienture beats Crescent Biopharma on 8 of the 14 factors compared between the two stocks.
About Crescent Biopharma
Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.
About Scienture
Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.
Receive News & Ratings for Crescent Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crescent Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
